SEC Form 4
Alkermes Inc. plc (ALKS) insider trading
In the 12 months to Oct 24, 2026, 7 ALKS insiders reported open-market sales of $10.3M across 28 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $10.3M
- 28 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 26 of 28
- $7.4M of $10.3M sold (72%)
Who traded ALKS, and when
- Sale
- Sale, pre-arranged (10b5-1)
ALKS daily close from Oct 24, 2025 to Oct 23, 2026, between $27.20 and $55.22, last $43.63. 28 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Craig C. Hopkinson, EVP R&D, Chief Medical Officer: sold $3.7M across 13 filings, first filed Nov 3, 2025, last Sep 1, 2026. nancy lynn MD snyderman, Director: sold $2.2M across 1 filing, first filed Aug 3, 2026, last Aug 3, 2026. Shane Cooke, Director: sold $2.1M across 1 filing, first filed Feb 2, 2026, last Feb 2, 2026. Samuel Joseph Parisi, VP, Finance (Interim PAO): sold $888.8K across 2 filings, first filed Mar 4, 2026, last May 29, 2026. David Joseph Gaffin, EVP, CLO, Alkermes, Inc.: sold $735.3K across 8 filings, first filed Mar 4, 2026, last Oct 2, 2026. Christian Todd Nichols, SVP, Chief Commercial Officer: sold $552.9K across 2 filings, first filed Mar 4, 2026, last Aug 17, 2026. Christopher I. Wright, Director: sold $90.2K across 1 filing, first filed Jun 12, 2026, last Jun 12, 2026.
Largest mark · tap a row for others
nancy lynn MD snyderman · Director
Sale $2,239,076
44,472 shares
Filed Aug 3, 2026
Close on filing date $49.53
Craig C. Hopkinson · EVP R&D, Chief Medical Officer
EVP R&D, Chief Medical Officer
$3.7M soldnancy lynn MD snyderman · Director
Director
$2.2M soldShane Cooke · Director
Director
$2.1M soldSamuel Joseph Parisi · VP, Finance (Interim PAO)
VP, Finance (Interim PAO)
$888.8K soldDavid Joseph Gaffin · EVP, CLO, Alkermes, Inc.
EVP, CLO, Alkermes, Inc.
$735.3K soldChristian Todd Nichols · SVP, Chief Commercial Officer
SVP, Chief Commercial Officer
$552.9K soldChristopher I. Wright · Director
Director
$90.2K soldHas Alkermes Inc. plc's CEO sold stock?
No. Blair Curtis Jackson and Richard F. Pops (CEOs) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
28 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | $3.7M | — | 13 | 100% of sales | |
| nancy lynn MD snyderman | Director | $2.2M | — | 1 | — | |
| Shane Cooke | Director | $2.1M | — | 1 | 100% of sales | |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | $888.8K | — | 2 | 23% of sales | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | $735.3K | — | 8 | 100% of sales | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | $552.9K | — | 2 | 100% of sales | |
| Christopher I. Wright | Director | $90.2K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $83.5K | 221,388 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $97.7K | 223,422 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $422.9K | 65,389 | |
traded | Christian Todd Nichols SVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 7,576 ordinary shares | $372.9K | 102,193 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $98.8K | 225,456 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $437.2K | 69,389 | |
traded | nancy lynn MD snyderman Director | Sale | 44,472 ordinary shares | $2.2M | 15,395 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $109.9K | 227,490 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $463.6K | 73,389 | |
traded | Christopher I. Wright Director | SalePre-arranged (10b5-1) | 2,000 ordinary shares | $90.2K | 25,680 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $87.6K | 229,524 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $375.0K | 77,389 | |
traded | Samuel Joseph Parisi VP, Finance (Interim PAO) | Sale | 16,217 ordinary shares | $687.0K | 7,717 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $67.5K | 231,558 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $300.6K | 81,389 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 2,034 ordinary shares | $70.3K | 233,592 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $319.6K | 85,389 | |
traded | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | SalePre-arranged (10b5-1) | 4,068 ordinary shares | $120.1K | 235,626 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $267.5K | 89,389 | |
traded | Christian Todd Nichols SVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 6,000 ordinary shares | $180.0K | 109,769 | |
traded | Samuel Joseph Parisi VP, Finance (Interim PAO) | SalePre-arranged (10b5-1) | 6,890 ordinary shares | $201.8K | 7,717 | |
traded | Shane Cooke Director | SalePre-arranged (10b5-1) | 61,200 ordinary shares | $2.1M | 135,857 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $305.4K | 57,740 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 5,000 ordinary shares | $150.0K | 61,740 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 4,000 ordinary shares | $112.0K | 61,740 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 3,748 ordinary shares | $112.4K | 65,740 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 4,000 ordinary shares | $117.2K | 65,740 | |
traded | Craig C. Hopkinson EVP R&D, Chief Medical Officer | SalePre-arranged (10b5-1) | 9,000 ordinary shares | $273.4K | 69,740 |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=ALKS&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ALKS"
],
"issuer_cik": "0001520262",
"owner_cik": "0001675905",
"accession_number": "0001520262-26-000127",
"form_type": "4",
"filing_date": "2026-10-02",
"period_of_report": "2026-10-02",
"issuer_name": "Alkermes plc.",
"issuer_trading_symbol": "ALKS",
"owner_name": "Gaffin David Joseph",
"is_officer": true,
"officer_title": "EVP, CLO, Alkermes, Inc.",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2034,
"transaction_price_per_share": 41.03,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 221388,
"transaction_value": 83455.02,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/19/2025."
}
]
},
{
"tickers": [
"ALKS"
],
"issuer_cik": "0001520262",
"owner_cik": "0001675905",
"accession_number": "0001520262-26-000120",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-03",
"issuer_name": "Alkermes plc.",
"issuer_trading_symbol": "ALKS",
"owner_name": "Gaffin David Joseph",
"is_officer": true,
"officer_title": "EVP, CLO, Alkermes, Inc.",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2034,
"transaction_price_per_share": 48.01,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 223422,
"transaction_value": 97652.34,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/19/2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 87 records
- Option exercises47 records
- Tax withholding35 records
- Grants and awards5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ALKS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.